Abbisko Cayman (HKG:2256) unit Abbisko Therapeutics entered a research and license partnership with Eli Lilly to develop new medicines, according to a Wednesday filing with the Hong Kong bourse.
The firm will receive an upfront payment, as well as milestone payments totaling up to $1.9 billion. The company will also received royalties on drugs commercialized as a result of the partnership.